Recent reports showed IDH1 mutations in astrocytic and oligodendroglial tumors (WHO grade II and III) and in secondary glioblastomas with a frequency of up to 90%, whereas IDH1 mutations occurred in only 5% of primary glioblastomas [14]. This evidence concerns the gene IDH1 and glioblastoma.